1. Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, et al. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract. 1999; 7:59–65.
Article
2. Passik SD, Kirsh KL, Rosenfeld B, McDonald MV, Theobald DE. The changeable nature of patients' fears regarding chemotherapy: implications for palliative care. J Pain Symptom Manage. 2001; 21:113–20.
3. Fernandez-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer. 2012; 20:3141–8.
Article
4. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003; 21:4112–9.
Article
5. Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother. 2003; 4:2297–303.
Article
6. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003; 98:2473–82.
7. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003; 14:1570–7.
Article
9. Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc). 2002; 38:75–89.
Article
10. Kim JS, Kim JY, Lee SJ, Park DK, Namgung H, Kim CN, et al. Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer. Ann Surg Treat Res. 2014; 87:9–13.
Article
11. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003; 11:522–7.
12. Rhodes VA. Criteria for assessment of nausea, vomiting, and retching. Oncol Nurs Forum. 1997; 24(7 Suppl):13–9.
14. Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 2016; 27:1601–6.
Article
15. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011; 9:188–95.
Article
16. Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014; 25:1340–6.
Article
17. Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, et al. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol. 2015; 26:1248–53.
Article
18. Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014; 25:1333–9.
Article
19. Wu F, Lin X, Yang Z, Sun Z, Zeng F, Heng J, et al. Phase III randomized trial of palonosetron and dexamethasone with or without aprepitant to prevent nausea and vomiting induced by full-dose single-day cisplatin-based chemotherapy in lung cancer. Clin Lung Cancer. 2018; 19:e913–8.
Article
20. Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018; 29:452–8.
Article
21. Kim HJ, Shin SW, Song EK, Lee NR, Kim JS, Ahn JS, et al. Ramosetron versus ondansetron in combination with aprepitant and dexamethasone for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: a multicenter, randomized phase III trial, KCSG PC10-21. Oncologist. 2015; 20:1440–7.
Article
22. Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J Pharmacol Sci. 2007; 104:263–73.
Article